COVID-19 vaccination perception and uptake among cancer patients in Guangzhou, China.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE
    • Publication Information:
      Publication: 2015- : Philadelphia, PA : Taylor & Francis
      Original Publication: Austin, Tex. : Landes Bioscience
    • Subject Terms:
      COVID-19*/prevention & control ; Neoplasms*/complications ; Neoplasms*/therapy; Humans ; COVID-19 Vaccines ; Cross-Sectional Studies ; Vaccination ; China/epidemiology ; Perception
    • Abstract:
      Patients with cancer are considered at high risk of COVID-19 related complications with higher mortality rates than healthy individuals. This study investigated the perception, acceptance, and influencing factors of COVID-19 vaccination among cancer patients in Guangzhou, China. A cross-sectional survey was conducted in Guangzhou, China from August to November 2021 in two tertiary medical centers. Outpatients were recruited through hospital posters to complete a questionnaire including demographics, medical history, knowledge, and attitude toward COVID-19 vaccines and COVID-19 vaccination status. Chi-square tests and multivariable logistic regression were used to analyze predictors for acceptance of COVID-19 vaccination. In total, only 75 out of 343 patients (21.87%) had received at least one dose of COVID-19 vaccine. Twenty-one patients (6.12%) had received a recommendation about COVID-19 vaccination from their physicians. Patients who were recommended by physicians to get vaccinated (aOR = 11.71 95% CI: 2.71-50.66), with a monthly income of more than CNY 5000 (aOR = 3.94, 95% CI: 1.88-8.26) were more likely to have received COVID-19 vaccination. Cancer patients who had been diagnosed for more than one year (aOR = 0.21, 95% CI: 0.09-0.51), had received multiple cancer treatment strategies (aOR = 0.34, 95% CI: 0.16-0.74), worried about the safety of COVID-19 vaccines (aOR = 0.21, 95% CI: 0.11-0.40), were less likely to have received COVID-19 vaccination. COVID-19 vaccination uptake among cancer patients was insufficient. The proportion of cancer patients receiving vaccination recommendations from physicians remains inadequate. Physicians are expected to play an essential role in patients' knowledge of the safety and effectiveness of COVID-19 vaccines.
    • References:
      Ann Intern Med. 2020 Dec 15;173(12):964-973. (PMID: 32886525)
      J Integr Med. 2022 Jan;20(1):34-44. (PMID: 34774463)
      Lancet. 2020 Jun 20;395(10241):1907-1918. (PMID: 32473681)
      JAMA Oncol. 2021 Aug 1;7(8):1133-1140. (PMID: 34047765)
      Asian Pac J Cancer Prev. 2021 Nov 01;22(11):3499-3506. (PMID: 34837905)
      Cancer Discov. 2021 Feb;11(2):233-236. (PMID: 33355178)
      J Natl Med Assoc. 2020 Dec;112(6):681-687. (PMID: 33276969)
      Nat Rev Clin Oncol. 2021 May;18(5):313-319. (PMID: 33723371)
      Lancet Oncol. 2020 Mar;21(3):335-337. (PMID: 32066541)
      Ann Oncol. 2021 Aug;32(8):1051-1053. (PMID: 33932501)
      Infect Drug Resist. 2021 Nov 23;14:4865-4876. (PMID: 34848979)
      Healthcare (Basel). 2021 Mar 19;9(3):. (PMID: 33808758)
      Hum Vaccin Immunother. 2021 Dec 2;17(12):4971-4981. (PMID: 34890297)
      Adv Drug Deliv Rev. 2021 Mar;170:1-25. (PMID: 33359141)
      J Infect. 2020 Aug;81(2):e16-e25. (PMID: 32335169)
      J BUON. 2021 Sep-Oct;26(5):2183-2190. (PMID: 34761633)
      Lancet Infect Dis. 2021 Feb;21(2):e26-e35. (PMID: 33125914)
      Vaccines (Basel). 2021 Apr 21;9(5):. (PMID: 33919048)
      Eur J Cancer. 2020 Nov;139:43-50. (PMID: 32971510)
      Cancers (Basel). 2021 Jul 16;13(14):. (PMID: 34298785)
      Front Oncol. 2021 Nov 04;11:759108. (PMID: 34804957)
      J Immigr Minor Health. 2019 Apr;21(2):299-305. (PMID: 29603088)
      Aging Male. 2020 Dec;23(5):1416-1424. (PMID: 32508193)
      Eur J Cancer. 2021 Dec;159:259-274. (PMID: 34798454)
      Cancers (Basel). 2021 Aug 01;13(15):. (PMID: 34359783)
      J Infect. 2020 Jun;80(6):656-665. (PMID: 32283155)
      Am J Public Health. 2021 Mar;111(3):355-358. (PMID: 33237801)
      Lancet Oncol. 2021 May;22(5):581-583. (PMID: 33812495)
      Ann Oncol. 2021 May;32(5):673-674. (PMID: 33529740)
      J Community Health. 2021 Apr;46(2):270-277. (PMID: 33389421)
      Lancet Oncol. 2021 Jun;22(6):765-778. (PMID: 33930323)
      Vaccine. 2015 Mar 30;33(14):1682-7. (PMID: 25720791)
      Clin Infect Dis. 2021 May 4;72(9):e206-e214. (PMID: 32674114)
      Front Oncol. 2021 Mar 25;11:652535. (PMID: 33842366)
    • Contributed Indexing:
      Keywords: COVID-19; China; cancer; predictors; vaccination
    • Accession Number:
      0 (COVID-19 Vaccines)
    • Publication Date:
      Date Created: 20220817 Date Completed: 20221216 Latest Revision: 20221221
    • Publication Date:
      20231215
    • Accession Number:
      PMC9746538
    • Accession Number:
      10.1080/21645515.2022.2102329
    • Accession Number:
      35976684